DNA-hsp65 Vaccine as Therapeutic Strategy to Treat Experimental Chromoblastomycosis Caused by FonsecaeaPedrosoi

Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi. Patients with the disease are still considered a therapeutic challenge, mainly due to its recalcitrant nature. There is no “gold standard” treatment for this neglected mycosis, but...

Full description

Saved in:
Bibliographic Details
Published in:Mycopathologia (1975) 2013-06, Vol.175 (5-6), p.463-475
Main Authors: Siqueira, Isaque Medeiros, Ribeiro, Alice Melo, de Medeiros Nóbrega, Yanna Karla, Simon, Karina Smidt, Souza, Ana Camila Oliveira, Jerônimo, Márcio Souza, Neto, Florêncio Figueiredo Cavalcante, Silva, Célio Lopes, Felipe, Maria Sueli Soares, Bocca, Anamélia Lorenzetti
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Cell growth
Chemotherapy
Chronic illnesses
Disease
Eukaryotic Microbiology
Fungal infections
Heat shock proteins
Life Sciences
Medical Microbiology
Microbial Ecology
Microbiology
Plant Sciences
Toxicity
Tuberculosis
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi. Patients with the disease are still considered a therapeutic challenge, mainly due to its recalcitrant nature. There is no “gold standard” treatment for this neglected mycosis, but rather there are several treatment options. Chemotherapy alternatives include 5-flucytosine, itraconazole, terbinafine, fluconazole, thiabendazole, ketoconazole and amphotericin B, although the healing of severe cases is still uncommon. However, several studies have reported the DNA vaccine to be promising in the treatment for fungal infections; this vaccine allows the host to restore depressed cellular immunity, minimizing the toxic effects from conventional antifungal therapies. This work was therefore carried out aiming to establish a suitable model for experimental CBM, suggesting also new therapies, including DNA-hsp65 vaccine. By analyzing the morphometrical and histopathological aspects and by quantifying the fungal burden, the results showed the establishment of a chronic, although transitory, experimental CBM model with lesions similar to those presented in humans. A treatment regimen using intralesional itraconazole or amphotericin B was effective in treating experimental CBM, as was a therapy using naked DNA-hsp65 vaccine. It has also been shown that chemotherapy associated with DNA-hsp65 vaccine is promising in the treatment for CBM.
ISSN:0301-486X
1573-0832
DOI:10.1007/s11046-012-9599-7